Mallinckrodt has announced it will acquire Sucampo Pharmaceuticals, including its commercial and development assets. The transaction was approved by the Boards of Directors of both companies.   “Mallinckrodt’s acquisition of Sucampo is the latest milestone towards our vision of becoming an innovation-driven specialty pharmaceutical growth company focused on improving outcomes for patients with severe and critical conditions,” said Mark Trudeau, chief executive officer a...